Want to see HK:1302 full AI Analyst Report?
1302 Stock Chart & Stats
HK$1.58
HK$0.01(0.75%)
At close: 4:00 PM EST
HK$1.58
HK$0.01(0.75%)
Day’s Range― - ―
52-Week RangeHK$1.30 - HK$2.44
Previous CloseN/A
Volume6.38M
Average Volume (3M)26.58M
Market Cap
HK$6.26B
Enterprise ValueHK$5.58K
Total Cash (Recent Filing)HK$1.20B
Total Debt (Recent Filing)HK$8.04M
Price to Earnings (P/E)35.7
Beta0.91
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding4,631,712,400
10 Day Avg. Volume33,345,600
30 Day Avg. Volume26,582,987
Financial Highlights & Ratios
PEG Ratio-1.21
Price to Book (P/B)1.79
Price to Sales (P/S)4.58
P/FCF Ratio12.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.06
Revenue Forecast (FY)HK$1.47B
Bulls Say, Bears Say
Bulls Say
Revenue Re-accelerationSustained double-digit top-line re-acceleration demonstrates renewed product adoption and market penetration in 2025. Durable revenue momentum supports scale economies, funds continued R&D and geographic expansion, and increases the runway to rebuild margins if maintained over quarters.
Very Low LeverageAn exceptionally conservative balance sheet with minimal debt reduces financial risk and preserves strategic optionality. It enables the company to absorb cyclical downturns, pursue bolt-on M&A, or increase investment in sales and product development without immediate refinancing pressure.
Strong FCF Conversion (2025)High free-cash-flow and near-par conversion to net income in 2025 indicate the business can convert profits into cash resources. This strengthens capacity to self-fund capex, clinical/regulatory programs, or shareholder returns and supports longer-term investment even as growth scales.
Bears Say
Margin & ROE CompressionMaterial decline in net margins and return on equity over multiple years signals weakened profitability and capital efficiency. If structural, this reduces internal funding for innovation and expansion, pressures investor returns, and suggests competitiveness or cost issues that must be resolved to restore durable profitability.
Variable Cash ConversionInconsistent cash conversion and modest operating cash relative to reported profits create unpredictability in available funds for capex and growth. This variability raises execution risk, complicates budgeting for clinical or commercial expansion, and can force reliance on external financing despite low leverage.
Operating Margin DeteriorationA sustained step-down in operating margins suggests rising costs or pricing pressure in the medical-device markets. Lower operating profitability constrains reinvestment into product development and sales capacity, potentially eroding long-term competitive position absent structural cost or pricing remedies.
LifeTech Scientific Corporation News
1302 FAQ
What was LifeTech Scientific Corporation’s price range in the past 12 months?
LifeTech Scientific Corporation lowest stock price was HK$1.30 and its highest was HK$2.44 in the past 12 months.
What is LifeTech Scientific Corporation’s market cap?
LifeTech Scientific Corporation’s market cap is HK$6.26B.
When is LifeTech Scientific Corporation’s upcoming earnings report date?
LifeTech Scientific Corporation’s upcoming earnings report date is Aug 28, 2026 which is in 14 days.
How were LifeTech Scientific Corporation’s earnings last quarter?
LifeTech Scientific Corporation released its earnings results on Mar 31, 2026. The company reported HK$0.023 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is LifeTech Scientific Corporation overvalued?
According to Wall Street analysts LifeTech Scientific Corporation’s price is currently Overvalued.
Does LifeTech Scientific Corporation pay dividends?
LifeTech Scientific Corporation does not currently pay dividends.
What is LifeTech Scientific Corporation’s EPS estimate?
LifeTech Scientific Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LifeTech Scientific Corporation have?
LifeTech Scientific Corporation has 4,631,712,400 shares outstanding.
What happened to LifeTech Scientific Corporation’s price movement after its last earnings report?
LifeTech Scientific Corporation reported an EPS of HK$0.023 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.545%.
Which hedge fund is a major shareholder of LifeTech Scientific Corporation?
Currently, no hedge funds are holding shares in HK:1302
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LifeTech Scientific Corporation Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.05%
Trailing 12-Months
Company Description
LifeTech Scientific Corporation
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders in Mainland China, Europe, Rest of Asia, India, South America, Africa, and internationally. It operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac Pacing and Electrophysiology Business segments. The company’s products include LAmbre left atrial appendage closure systems, as well as CeraFlex, Cera, HeartR, and Konar-MF VSD occluders; Ankura thoracic aortic aneurysm and abdominal aortic aneurysm stent graft systems; Futhrough endovascular needle systems; delivery systems, such as Fustar steerable and SteerEase introducers; Zoetrack guidewire; Aegisy vena cava filters; Cera vascular plug systems; AcuMark sizing balloons; HearTone implantable cardiac pacing system; and SeQure snare systems, as well as pacemakers. It also involved in the biomedical research and development; properties leasing business; and developing, manufacturing, and trading of medical devices, as well as offers technical, consulting, and technology services. LifeTech Scientific Corporation was founded in 1999 and is headquartered in Shenzhen, China.
Technical Analysis
MicroPort Scientific
―
Peijia Medical Ltd.
―
AK Medical Holdings Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
MicroPort NeuroTech Limited
―